Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02889861 · ClinicalTrials.gov registry record · Phase 2
IMCgp100-401 Rollover Study
A Phase 2 study, sponsored by Immunocore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02889861 is a Phase 2 study that was terminated before completion, run by Immunocore. The registered enrollment target is 3 participants.
The verdict
NCT02889861, a Phase 2 study, was terminated before completion, sponsored by Immunocore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
Interventions
- DRUG IMCgp100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02889861
The ClinicalTrials.gov registry entry for NCT02889861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 is the first listed.
NCT02889861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02889861 about?
NCT02889861 is a clinical study titled "IMCgp100-401 Rollover Study". IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
What is the current status of trial NCT02889861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-01-11. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT02889861?
The interventions under investigation include: IMCgp100 (DRUG).
Who is sponsoring clinical trial NCT02889861?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.